Contributor: Focus on the Real Causes of the Shortage in Hormone Treatments

Why It Matters

The episode highlights how PBM‑driven vertical integration can jeopardize access to essential, low‑cost medicines, signaling broader risks for generic drug availability across the U.S. healthcare system.

Key Takeaways

• Estradiol patch shortage stems from PBM-driven insurance structures
• Generic estradiol use dropped to 1.8% in 2024
• CVS Caremark, Express Scripts, OptumRx control 79% of U.S. drug claims
• PBMs incentivize branded alternatives, limiting generic access
• Patients can seek online or compounding pharmacies for patches

Pulse Analysis

The estradiol patch, a decades‑old transdermal hormone therapy, has become a flashpoint for a deeper supply‑chain flaw. While headlines blame a "menopause moment" and soaring demand, data from Truveta shows hormone‑replacement usage plateaued at roughly five percent of eligible women in 2024—far below the pre‑2002 peak. The patch’s formulation is chemically simple, with multiple generic manufacturers, yet pharmacies repeatedly report stockouts, indicating that demand alone cannot explain the shortage.

The root cause lies in the concentration of pharmacy‑benefit managers (PBMs) owned by the nation’s largest insurers. CVS Caremark, Express Scripts and OptumRx together process nearly eight‑tenths of all prescription claims, giving them decisive power over formularies, reimbursement rates, and distribution priorities. Because estradiol patches generate minimal profit, PBMs have little financial motive to maintain robust inventories, often steering patients toward higher‑margin branded alternatives. The FTC’s recent report underscores how this model inflates costs, squeezes independent pharmacies, and erodes access to generic drugs—a pattern now evident in hormone therapy, blood thinners, inhalers, and antibiotics.

For patients navigating the shortage, practical workarounds include asking prescribers for alternative estradiol formulations, using reputable online pharmacies that bypass traditional PBM channels, and exploring compounding pharmacies that can produce equivalent doses. On a systemic level, lawmakers are considering legislation to curb PBM dominance and increase transparency, while the FDA could pressure manufacturers to improve supply reliability. Addressing the structural incentives that deprioritize low‑margin generics will be essential to prevent future shortages of essential therapies like the estradiol patch.